31 August 2022
Coloplast is hosting a Meet the Management event in Humlebæk, Denmark, today at 11:30 CEST, where the company will provide a progress update on its Strive25 strategy.
The event will start with a plenary session, covering a brief financial update on Q3 2021/22, followed by an update on the Strive25 strategy with a key focus on Innovation and the recent acquisition of Atos Medical.
In the afternoon, there will be a series of breakout sessions with Executive Management and other key representatives from Coloplast, covering the Clinical Performance Program and Market Development, Chronic Care and Wound and Skin Care, Interventional Urology, and Global Operations and Finance.
Key highlights of the day are:
- The ambition set with the Strive25 strategy of 7-9% organic growth and more than 30% EBIT margin for the strategic period is confirmed
- Solid progress on the Clinical Performance Program, with the first major launch of the new catheter platform expected in FY 2022/23
- Chronic Care has largely recovered from the COVID-19 impact, except for China; Coloplast continues to gain market share across geographies
- Solid progress in the US Ostomy Care business on the back of the GPO wins and sales force expansion
- Interventional Urology is progressing in line with the Strive25 ambitions; new product launches starting end of FY 2021/22
- Wound & Skin performing in line with the Strive25 ambitions, despite COVID-19 impact in China
- Performance and integration of Atos Medical are on track
- The Global Operations Plan 5 is challenged by increasing input costs; the automation program and Costa Rica are progressing as expected
The plenary session will be webcasted live, with a possibility to join virtually. The breakout sessions are in-person only, but a recording of the presentations will be available later the same day.
All relevant material and the chat function for the plenary session can be found here: Coloplast Meet the Management (getvisualtv.net).
For further information, please contact
Investors and analysts
Anders Lonning-Skovgaard
Executive Vice President, CFO
Tel. +45 4911 1111
Aleksandra Dimovska
Director, Investor Relations
Tel. +45 4911 1800 / +45 4911 2458
Email: dkadim@coloplast.com
Kristine Husted Munk
Senior Manager, Investor Relations
Tel. +45 4911 1800 / +45 4911 3266
Email: dkkhu@coloplast.com
Press and media
Peter Mønster
Sr. Media Relations Manager
Tel. +45 4911 2623
Email: dkpete@coloplast.com
Address
Coloplast A/S
Holtedam 1
DK-3050 Humlebaek
Denmark
Company reg. (CVR) no. 69749917
Website
www.coloplast.com
This announcement is available in a Danish and an English-language version. In the event of discrepancies, the Danish version shall prevail.
Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate health care. Our business includes Ostomy Care, Continence Care, Wound and Skin Care, Interventional Urology and Voice & Respiratory Care. We operate globally and employ about 14,000 employees.
The Coloplast logo is a registered trademark of Coloplast A/S. © 2022-08.
All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.
Attachment
